Gut Microbiome and Metabolites in Systemic Lupus Erythematosus: Link, Mechanisms and Intervention

Lingshu Zhang†, Pingying Qing†, Hang Yang†, Yongkang Wu², Yi Liu¹ and Yubin Luo¹*

¹Department of Rheumatology and Immunology, Rare Diseases Center, Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China, ²Department of Laboratory Medicine and Outpatient, West China Hospital, Sichuan University, Chengdu, China

Systemic lupus erythematosus (SLE), often considered the prototype of autoimmune diseases, is characterized by over-activation of the autoimmune system with abnormal functions of innate and adaptive immune cells and the production of a large number of autoantibodies against nuclear components. Given the highly complex and heterogeneous nature of SLE, the pathogenesis of this disease remains incompletely understood and is presumed to involve both genetic and environmental factors. Currently, disturbance of the gut microbiota has emerged as a novel player involved in the pathogenesis of SLE. With in-depth research, the understanding of the intestinal bacteria-host interaction in SLE is much more comprehensive. Recent years have also seen an increase in metabolomics studies in SLE with the attempt to identify potential biomarkers for diagnosis or disease activity monitoring. An intricate relationship between gut microbiome changes and metabolic alterations could help explain the mechanisms by which gut bacteria play roles in the pathogenesis of SLE. Here, we review the role of microbiota dysbiosis in the aetiology of SLE and how intestinal microbiota interact with the host metabolism axis. A proposed treatment strategy for SLE based on gut microbiome (GM) regulation is also discussed in this review. Increasing our understanding of gut microbiota and their function in lupus will provide us with novel opportunities to develop effective and precise diagnostic strategies and to explore potential microbiota-based treatments for patients with lupus.

Keywords: Systemic lupus erythematosus, gut microbiota dysbiosis, metabolites, SLE pathogenesis, SLE therapy

INTRODUCTION

Systemic lupus erythematosus (SLE) is one of the most common systematic autoimmune diseases. It predominantly affects women of childbearing age and targets a diverse array of organs, including the skin, joints, kidney, lung, heart, and gastrointestinal tract, among others. Almost all SLE patients present with a large number of detectable autoantibodies against nucleic acid-(DNA or RNA)-associated proteins, with a particular emphasis on antinuclear antibodies (ANAs), anti-double stranded DNA (anti-dsDNA) antibodies, anti-Smith (Sm) antibodies, and anti-Sjögren’s syndrome-related antigens A and B (SSA/Ro and SSB/La, respectively) (1, 2). The heterogeneous clinical presentation of SLE indicates its complex aetiology. Although dozens of associated genomic variations have been identified by genomic analyses, the identified loci account for only 28% or
less of disease heritability (3, 4). It is still puzzling how each variant functions in the pathogenesis of SLE. It is known that adaptive immune network dysregulation plays a significant role in the pathogenesis of SLE, in which abnormal T and B cell activation, self-antigen exposure and impaired apoptotic pathways contribute to a high frequency of autoantibody production in lupus (5, 6). Additionally, signal transducer and activator of transcription 4 (STAT4), interferon regulatory factor 5 (IRF5), IRF7, Toll-like receptor 7 (TLR7) and TLR9 are involved in pro-inflammatory cytokine production in monocytes/macrophages and type I interferon (IFN) production by dendritic cells (DCs), which induce and aggravate local and systemic inflammation in SLE (7, 8). However, the underlying molecular basis for the multifaceted manifestations of SLE is still indeterminate.

Environmental factors have also been postulated to be important triggers for initiating and promoting autoimmune reactions associated with SLE (9, 10). The microorganisms within our environment mainly include bacteria, protozoa, fungi, rickettsiae, viruses and helminths. The original research focusing on human-associated microbiota dates back to the 17th century (11), and the advent of high-throughput sequencing techniques represents a powerful tool to enhance our understanding of the biological activity of gut microbes (12–15). Within microbiome communities, Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria are four major phyla necessary to maintain a physiological gut bacterial ecosystem and homeostasis at distal sites. Gut microbes contribute to metabolic processes, the production of necessary secondary metabolites, and the shaping of host immunity (16). Within the previous two decades, expanding research has linked autoimmune diseases and intestinal bacterial composition changes (17–21). A fundamental role of the intestinal microbiome in the host is to help the mammalian intestinal immune system mature and protect the host from pathogen invasion by initiating pattern-recognition receptors (PRRs) in mucosal sites by expressing microorganism-associated molecular patterns (22). Changing the profile of metabolites is another important way in which gut bacteria affect host immune homeostasis. Regardless of whether the metabolites are solely derived from bacteria or drawn by co-metabolized bacteria and the host, their alteration commonly results in a local or systemic immune response change (23, 24). Elucidating the crosstalk between commensal microbiota, metabolites and the immune system may be crucial to understanding the immunopathology of SLE.

In this review, we aim to compile the available advances in understanding how gut microbiota functionally affect the development of various autoantibodies and how bacteria-derived metabolites contribute to inflammation and the interaction between intestinal microbiota and medication in the pathogenesis of SLE. Moreover, we also present evidence- or hypothesis-based perspectives for new therapeutic strategies for SLE.

**THE GUT MICROBIOTA IN SLE**

Mounting evidence suggests that a wide range of autoimmune conditions have characteristic patterns of gut microbiome dysbiosis, such as inflammatory bowel disease (IBD) (18), diabetes (19), multiple sclerosis (25) and rheumatoid arthritis (RA) (21). A link between gut microbiota populations and SLE has also been proposed recently.

**The Link Between GM Dysbiosis and SLE in Humans**

Since gut symptoms are not specific and typical in SLE patients, the link between gut bacteria and SLE development was neglected by the rheumatologists or scientists before. This streak was broken by Hevia et al. in 2014, who reported that patients with lupus presented restricted gut microbiome diversity compared with 20 healthy counterparts (26). In addition, patients with SLE also have altered structure and composition of the gut microbiota, and the proportions of bacteria at multiple levels differ from healthy individuals, including the enrichment of Proteobacteria, Bacteroidetes and Actinobacteria and a lower proportion of Firmicutes compared with healthy controls (27).

The Firmicutes/Bacteroides (F/B) ratio is contradictory in some studies, which is probably because of the differences in the enrolment criteria of patients, including race, sex ratio, active disease duration, and immune therapy methods (Table 1).

Interestingly, SLE-related gut microbiota share some similarities across geographical locations, as observed in a study examining SLE subjects from Spain and China. Both groups showed an enrichment of Prevotellaceae when compared to their healthy counterparts (27). However, a depletion of Lachnospiraceae and Ruminococcaceae species and a significant increase in Bacteroidaceae were detected in patients from Spain compared to those from China (26). Another microbial population of interest in autoimmune disorders is Prevotella. A flourishing dietary structure and genetic background may contribute to intestinal disturbances in different populations with autoimmune disorders. Interestingly, the genera Rhodococcus, Egerthella, Klebsiella, Prevotella, Eubacterium, Flavonifractor and Incertae sedis are significantly prevalent in SLE patients, while the genera Dialister and Pseudobutyrivibrio are considerably reduced (Table 1) (27). At the species level, Ruminococcus gravis (RG) of the Firmicutes phylum thrives in the gastrointestinal tract and promotes gut barrier impairment, which is especially prominent in SLE patients with renal involvement. Moreover, species richness diversity was directly paralleled with the SLE disease activity index (SLEDAI) (28). Furthermore, anti-RG antibodies are positively correlated with the SLEDAI score and anti-native DNA levels but negatively correlated with C3 and C4 levels (Table 1) (28).

**The Effect of GM Dysbiosis on Immune Cells in SLE**

More recent detailed studies point to the effects of GM dysbiosis in SLE patients on immune cell phenotype switching and functions, which further proves their importance in immunological tolerance breaks in SLE. T cells, B cells and plasmacytoid dendritic cells (pDCs) are pivotal immune cells implicated in SLE pathogenesis (10). *Prevotella* cultures are strongly associated with augmented T helper type 17 (Th17)-mediated mucosal inflammation and the production of interleukin (IL)-8, IL-6 and CCL20 through the stimulation of epithelial cells, leading to local or systemic chronic inflammation (36). Some *Prevotella* strains play an important role in intestinal
The production of dozens of autoimmune antibodies is a major characteristic of systemic autoimmune disease; however, the mechanisms of their overexpression remain unclear. ANAs are a hallmark feature of SLE, systemic sclerosis (SSc), and polymyositis, making them the most sensitive and effective biomarker for the diagnosis of a systemic autoimmune disease. Almost all lupus patients produce high titres of ANA for years prior to the appearance of clinical symptoms.

Anti-DNA antibodies were originally described in patients with bacterial infections in the late 1930s (43). Since 1957, anti-DNA antibodies have been discovered in lupus patients (44–46), and antibodies directed against dsDNA have been associated with SLE disease severity. Anti-dsDNA antibodies are specific autoantigens targeted in SLE with a high SLEDAI. The levels of anti-dsDNA antibodies are related to the severity of nephritis (47, 48) and sufficient for SLE classification in both the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (49) and the 2019 European League Against Rheumatism (EULAR)/ACR classification criteria (50, 51). Patients with lupus have intestinal dysbiosis accompanied by reduced diversity richness of microbiota compared to healthy controls. Some species like the relative abundance of Bacteroides vulgatus, Bacteroides uniformis and Bacteroides ovatus was significantly higher in SLE patients than in population controls (Table 1) (30). A recent study reported that lupus patients have impaired intestinal barrier integrity and possess a striking fivefold increase in the abundance of intestinal Ruminococcus gravis (RG). Moreover, serum anti-RG strain-restricted antibodies were correlated with SLEDAI score and active nephritis.

Antibodies directed against dsDNA have been associated with SLE disease severity. Anti-dsDNA antibodies are specific autoantigens targeted in SLE with a high SLEDAI. The levels of anti-dsDNA antibodies are related to the severity of nephritis (47, 48) and sufficient for SLE classification in both the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (49) and the 2019 European League Against Rheumatism (EULAR)/ACR classification criteria (50, 51). Patients with lupus have intestinal dysbiosis accompanied by reduced diversity richness of microbiota compared to healthy controls. Some species like the relative abundance of Bacteroides vulgatus, Bacteroides uniformis and Bacteroides ovatus was significantly higher in SLE patients than in population controls (Table 1) (30). A recent study reported that lupus patients have impaired intestinal barrier integrity and possess a striking fivefold increase in the abundance of intestinal Ruminococcus gravis (RG). Moreover, serum anti-RG strain-restricted antibodies were correlated with SLEDAI score and active nephritis.

**The Effects of GM Dysbiosis on Lupus-Related Antibody Production**

The production of dozens of autoimmune antibodies is a major characteristic of systemic autoimmune disease; however, the mechanisms of their overexpression remain unclear. ANAs are a hallmark feature of SLE, systemic sclerosis (SSc), and polymyositis, making them the most sensitive and effective biomarker for the diagnosis of a systemic autoimmune disease. Almost all lupus patients produce high titres of ANA for years prior to the appearance of clinical symptoms.

Anti-DNA antibodies were originally described in patients with bacterial infections in the late 1930s (43). Since 1957, anti-DNA antibodies have been discovered in lupus patients (44–46), and antibodies directed against dsDNA have been associated with SLE disease severity. Anti-dsDNA antibodies are specific autoantigens targeted in SLE with a high SLEDAI. The levels of anti-dsDNA antibodies are related to the severity of nephritis (47, 48) and sufficient for SLE classification in both the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (49) and the 2019 European League Against Rheumatism (EULAR)/ACR classification criteria (50, 51). Patients with lupus have intestinal dysbiosis accompanied by reduced diversity richness of microbiota compared to healthy controls. Some species like the relative abundance of Bacteroides vulgatus, Bacteroides uniformis and Bacteroides ovatus was significantly higher in SLE patients than in population controls (Table 1) (30). A recent study reported that lupus patients have impaired intestinal barrier integrity and possess a striking fivefold increase in the abundance of intestinal Ruminococcus gravis (RG). Moreover, serum anti-RG strain-restricted antibodies were correlated with SLEDAI score and active nephritis.

**The Effects of GM Dysbiosis on Lupus-Related Antibody Production**

The production of dozens of autoimmune antibodies is a major characteristic of systemic autoimmune disease; however, the mechanisms of their overexpression remain unclear. ANAs are a hallmark feature of SLE, systemic sclerosis (SSc), and polymyositis, making them the most sensitive and effective biomarker for the diagnosis of a systemic autoimmune disease. Almost all lupus patients produce high titres of ANA for years prior to the appearance of clinical symptoms.

Anti-DNA antibodies were originally described in patients with bacterial infections in the late 1930s (43). Since 1957, anti-DNA antibodies have been discovered in lupus patients (44–46), and antibodies directed against dsDNA have been associated with SLE disease severity. Anti-dsDNA antibodies are specific autoantigens targeted in SLE with a high SLEDAI. The levels of anti-dsDNA antibodies are related to the severity of nephritis (47, 48) and sufficient for SLE classification in both the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (49) and the 2019 European League Against Rheumatism (EULAR)/ACR classification criteria (50, 51). Patients with lupus have intestinal dysbiosis accompanied by reduced diversity richness of microbiota compared to healthy controls. Some species like the relative abundance of Bacteroides vulgatus, Bacteroides uniformis and Bacteroides ovatus was significantly higher in SLE patients than in population controls (Table 1) (30). A recent study reported that lupus patients have impaired intestinal barrier integrity and possess a striking fivefold increase in the abundance of intestinal Ruminococcus gravis (RG). Moreover, serum anti-RG strain-restricted antibodies were correlated with SLEDAI score and active nephritis.

**The Effects of GM Dysbiosis on Lupus-Related Antibody Production**

The production of dozens of autoimmune antibodies is a major characteristic of systemic autoimmune disease; however, the mechanisms of their overexpression remain unclear. ANAs are a hallmark feature of SLE, systemic sclerosis (SSc), and polymyositis, making them the most sensitive and effective biomarker for the diagnosis of a systemic autoimmune disease. Almost all lupus patients produce high titres of ANA for years prior to the appearance of clinical symptoms.

Anti-DNA antibodies were originally described in patients with bacterial infections in the late 1930s (43). Since 1957, anti-DNA antibodies have been discovered in lupus patients (44–46), and antibodies directed against dsDNA have been associated with SLE disease severity. Anti-dsDNA antibodies are specific autoantigens targeted in SLE with a high SLEDAI. The levels of anti-dsDNA antibodies are related to the severity of nephritis (47, 48) and sufficient for SLE classification in both the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (49) and the 2019 European League Against Rheumatism (EULAR)/ACR classification criteria (50, 51). Patients with lupus have intestinal dysbiosis accompanied by reduced diversity richness of microbiota compared to healthy controls. Some species like the relative abundance of Bacteroides vulgatus, Bacteroides uniformis and Bacteroides ovatus was significantly higher in SLE patients than in population controls (Table 1) (30). A recent study reported that lupus patients have impaired intestinal barrier integrity and possess a striking fivefold increase in the abundance of intestinal Ruminococcus gravis (RG). Moreover, serum anti-RG strain-restricted antibodies were correlated with SLEDAI score and active nephritis.
antibodies was detected in those with active lupus nephritis (including class III and IV) (Table 1) (28). The transplantation of faeces from SLE mice to GF recipients resulted in an enhanced intestinal immune response and upregulated expression of antibody titres against dsDNA in GF mice in contrast to those that received B6 faeces (52).

Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by the presence of vascular thrombosis or pregnancy complications and anti-phospholipid antibodies, including lupus anticoagulant (LA), anticardiolipin antibody (aCL) and anti-beta 2 glycoprotein 1 (anti-β2 GPI) (53). APS was first described in lupus patients (54), and approximately 40% of lupus patients possess these antibodies (55). The presence of higher concentrations of IgA anti-β2GPI antibodies is associated with disease prevalence or morbidities involving the gastrointestinal system, pulmonary system, or skin and a higher risk of thromboembolic events, especially among lupus patients (56). A recent finding reported that the human gut commensal Roseburia intestinalis (R. int), a widely prevalent bacterium in the host, contains amino acid sequences that are highly homologous to sequences found in B and T cell epitopes within β2GPI (57). Significantly higher expression of faecal calprotectin was also identified in APS patients, indicating that subclinical intestinal and peripheral inflammation facilitates mucosal autoimmune responses to commensal bacteria, leading to systemic spread through cross-reactivity. Moreover, patients with APS experience the greatest levels of antibodies binding to a mimotope in a bacterial DNA methyltransferase expressed by R. int (R. int DNMT), and in these individuals, the induction of anti-R. int DNMT IgG surpassed that observed in healthy controls. Mice immunized with R. int lysates triggered a substantial rise in anti-rhβ2GPI autoantibody titres compared to B. theta- or sham-immunized controls in vivo. Furthermore, transplantation of R. int into a mouse model of spontaneous APS (NZW x BXSB) F1 triggered the development of anti-human-β2GPI antibodies and thrombotic events (57).

Taken together, the above studies indicate a close association between commensal microbiota and lupus-related antibodies. However, the implications of some specific bacteria in terms of immunological tolerance to self-antigens were not investigated and could only be suspected.

**GUT MICROBIOTA OF MURINE LUPUS MODELS**

**Gut Microbiome Dysbiosis and SLE Development—Evidence From Lupus Animal Models**

Emerging investigations in rodent models have confirmed the role of gut microbiota in the development of SLE. In an earlier study, Maldonado et al. did not observe a clinical difference between germ-free (GF) MRL/lpr mice and conventional mice. This difference appeared only when they were fed an unfiltered antigen-free diet (58). However, Johnson et al. then reported a significant and dynamic change in the gut microbiota communities before and after the onset of disease in lupus-prone (SWR × NZB) F1 mice (Table 2) (59). Interestingly, these female mice displayed more severe clinical lupus symptoms, associated with a higher abundance of a group of Lactobacillus in the gut compared to the male mice. In line with this finding, Zhang et al. observed an overrepresentation of Lachnospiraceae in female mice and an earlier onset of and/or more severe lupus symptoms (Table 2) (60), suggesting that the disturbed intestinal flora contributes to lupus development in a sex-dependent manner in mice.

**Potential Mechanisms Linking Intestinal Bacteria to SLE**

**Specific Bacterial Populations and Pathways Linked to the Microbiota and SLE**

The roles of Lactobacillus species in the pathogenesis of lupus-prone mice have been the most studied. Lactobacillus species are known for their capacity to harvest nutrients and generate energy but are commonly used as probiotic agents to regulate immune and anti-inflammatory responses (65). NZB/W F1 mice tend to have more diverse microbiota and enriched groups of Lactobacillus after dexamethasone treatment (Table 2) (31). The probiotics Lactobacillus rhamnosus and Lactobacillus delbrueckii were shown to downregulate the expression of miR-155 and miR-181a, which is positively correlated with the SLEDAI and kidney involvement in the PBMCs of SLE patients (66, 67). Lactobacillales has been reported to be markedly depleted in MRL/lpr mice, and increasing Lactobacillales can correct the leaky gut, promote IL-10, improve renal function, and prolong mouse survival (Table 2) (61). However, in 2019, Zegarra-Ruiz et al. identified an enrichment of another Lactobacillus species, Lactobacillus reuteri (L. reuteri), in lupus models. Unlike the other Lactobacillus species mentioned above, L. reuteri can worsen autoimmune manifestations by engaging in type I interferon pathways (Table 2) (32). Another interesting report is from Manfredo Vieira et al. Oral administration of antibiotics suppressed the growth of intestinal gram-positive bacterium Enterococcus gallinarum (E. gallinarum), leading to the intestinal epithelial tight junction decrease, the lupus-related autoantibodies reduction and the lifespan extension of lupus-prone mice. Vaccination with heat-killed E. gallinarum decreased serum autoantibodies and increased survival of the lupus-prone mice. E. gallinarum also found in liver biopsies of some SLE, but not control patients (Table 2). Moreover, the translocation of E. gallinarum from the intestine to the liver triggered innate autoimmunity by potently inducing IFN-α production by plasmacytoid dendritic cells and Th17 cell expansion through activation of the AhR pathway (62).

A mouse model of SLE, B6. NZM-Sle1NZM2410/Aeg-Sle2NZM2410/Aeg-Sle3NZM2410/Aeg [Lmo] mice, known as TC (SLE) mice, display anti-dsDNA antibodies in serum and immune cell disturbances (68). TC mice also exhibited restricted richness and diversity of microbiota compared with C57/B6 mice (B6 mice). Erysipelotrichia, unidentified Actinobacteria, Erysipelotrichales, Erysipelotrichaceae, Turricibacter were enriched in TC mice and Bacilli, Lactobacillales, Rikenellaceae, Lactobacillaceae, Alicettes, Lactobacillus were microbial makers in B6 mice. GF mice
TABLE 2 | Microbiota alteration in lupus-related mouse models.

| Model                          | Bacteria in disease                                                                 | Other                                                                 | Reference |
|-------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------|-----------|
| TC vs. C57BL/6 mice           | Class: Erysipelotrichia, unidentified Actinobacteria†; Bacill‡; Order: Erysipelotrichiales†; Lactobactiales†; Family: Erysipelotrichaceae†; Rikenellaceae†; Lactobacillaceae†; Genus: Turicibacter†; Alistipes†; Lactobacillus†. | Feces transplantation from TC mice to C57BL/6 germ-free mice induces anti-dsDNA antibodies and innate immune response. | (52)      |
| (SWR × NZB)F1 mice            | Phyllum: Firmicutes/Bacteroidetes ratio was not different; Family: Rikenellaceae†; Genus: Turicibacter spp.; Species: Lactobacillus reuteri†. | AW-fed mice have accelerated nephritis                              | (59)      |
| AW vs. NW                     |                                                                                      |                                                                      |           |
| MRL/pr vs. MRL mice           | Class: Clostridium, Dehalobacterium, Lactobacillus, Oscillospora, Dorea, Bilophila, AF12 and an unnamed genus within the family Ruminococcaceae†; Species: Akkermansia muciniphila and a species within the genus Anaerostipes†. | Lupus accelerated/more severe in females also associated with Lachnospiraceae†. | (60)      |
| NZB/W F1 mice                 |                                                                                      | Treatment with Dex decreases Lactobacilli which might be associated with progressing disease. | (31)      |
| MRL/pr vs. MRL mice           | Class: Blautia†; Desulfovibrio†; Species: Ruminococcus torques†.                     | Lactobacillus can correct the leaky gut, improve renal function and increase the survival of female lpr mice. | (61)      |
| TLR7.1 Tg vs. WT C57BL/6 mice | Species: Lactobacillus reuteri†.                                                      | Lactobacillus reuter increased plasmacytoid dendritic cells and interferon signaling. | (32)      |
| (NZW × BXSB)F1 vs. C57BL/6 mice | Class: Prevotellaceae, Paraprevotella and Lactobacill†.                               | Enterococcus gallinarum translocated from the intestine to the liver; vaccination with heat-killed E. gallinarum decreased serum autoantibodies and increased survival. E. gallinarum also found in liver biopsies of some SLE, but not control patients. | (62)      |
| MRL/pr vs. MRL/MpJ mice       | Class: Prevotellaceae, Paraprevotella and Lactobacill†.                               | Tryptophan metabolism was altered in TC mice; Prevotella species is associated with tryptophan metabolism. High tryptophan diet exacerbated and low tryptophan diet mitigated disease in TC mice and both diets altered microbiota and its ability to transfer disease to C57BL/6 germ-free mice. | (63)      |
| TC vs. C57BL/6 mice           | Class: Bacteroides, Parabacteroides†; Dysgonomonas†.                                  | Gender specific difference in gut microbiota appears at adult age.   | (64)      |
| (SWR × NZB)F1 mice            |                                                                                      |                                                                      |           |
| Female vs. Male               |                                                                                      |                                                                      |           |

AW, acidic pH water; NW, neutral pH water; Dex, dexamethasone; TLR7, Toll-like receptor 7; WT, wild-type; TC, B6.NZM-Sle1/NCr- SLE2/NCr- SLE3/NCr- LmoJ.
The bold type indicates the classification level of the bacteria.

As a highly conserved RNA-binding protein, orthologues of Ro60 are found in bacteria that reside at a variety of anatomical locations, including the skin, oral tract, and gut (74, 75). Cross-reactivity between Ro60 and EBV nuclear antigen-1 (EBNA-1) protein produced after EBV infection has been proposed as a mechanism for the progressive development of anti-Ro60 antibody in lupus patients (76). It has been reported that bacterial vWFA proteins expressed by E. coli can activate Ro60 reactive T-cell hybridomas in HLA-DR3 transgenic mice, demonstrating that peptides derived from commensal microbiota might be implicated in the initiation of autoimmune responses to Ro60 (77). Greiling et al. further demonstrated functional cross-reactivity between human Ro60 autoantigen-specific memory CD4 T cell clones from lupus patients and Ro60 orthologues from mucosal Ro60-containing species, including Bacteroides thetaiotaomicron, in vitro (Table 1). Mono-colonization of GF wild-type C57BL/6 mice with the common gut commensal B. thetaiotaomicron resulted in anti-Ro60 T and B cell responses in vivo (33). Another recent study also supports this molecular mimicry hypothesis in SLE. While certain species were found to be enriched in SLE patients, including Clostridium species ATCC BAA-442, Atopobium rimae, Shuttleworthia satelles, Actinomyces massiliensis, Bacteroides fragilis, and Clostridium leptum but reduced after treatment.

Molecular Mimicry

Another possible mechanism linking the intestinal microbiota to SLE pathogenesis is molecular mimicry (Figure 1). This hypothesis was addressed in two independent reports by Greiling et al. (33) and Chen et al. (34). Antibodies against Ro60/SSA/TROVE2, an evolutionarily conserved RNA-binding protein, are present in more than 50% of lupus patients (70). Ro60 is upregulated following ultraviolet (UV) irradiation (71, 72), which may trigger and flare the lupus disease process (73). Evidence from bacterial and animal cells supports a function for Ro60 in the mitigation of the environmental stress response (74).

administered SLE faeces had similar microbiota to their donors and showed significantly increased serum anti-dsDNA antibodies three weeks after faecal microbiota transplantation (FMT). Moreover, these mice possessed significantly higher percentages of plasma blasts, plasma cells and CD4⁺RORγ⁺ T cells but presented with a decreased proportion of Treg cells in the spleen, indicating that gut microbiota from TC mice has pivotal functions in immune response regulation (Table 2) (52). As the type-I IFN signalling pathway is critical in the pathogenesis of SLE (69), gut microbiota-derived IFN transcription may further enhance disease development by initiating downstream signalling of IFN (52).
Lactobacillus salivarius, Ruminococcus gnavus, Clostridium nexile, Olsenella uli, Actinomyces johnsonii, Staphylococcus aureus, Enterococcus avium were enriched in patients with lupus nephritis. Fecal *Clostridium* species ATCC BAA-442 and *Lactobacillus salivarius* correlated positively with SLEDAI. Moreover, the enrichment of oral species including *Actinomyces massiliensis*, *Shuttleworthia satelles*, *Clostridium* sp. ATCC BAA-442, *Bacteroides fragilis*, and *Clostridium leptum* in SLE suggests transmission rate of salivary microbes to intestine in SLE condition (Table 1). Genera *Desulfovibrio* was decreased while *Blautia* and *Ruminococcus torques* were increased in the gut of MRL/lpr (Table 2). In addition to the differences in the oral and gut microbiomes between healthy individuals and SLE patients, researchers also identified two peptides, “YLYDGRIFI” of *Odoribacter splanchnicus* significantly increases IFN-γ and IL-17A expression in PBMCs of a subgroup of anti-Sm-positive SLE patients. The peptide “DGQFCM” from *Akkermansia muciniphila* is capable of mimicking the extracellular part “DGQFCH” of human Fas and binds to IgG produced by memory B cells from SLE patients. Bacterial vWFA proteins expressed by *E. coli* can activate Ro60 reactive T cells.

Collectively, these investigations indicate microbial dysbiosis in the gut of SLE patients that results in reduced bacterial diversity and decreased proportions of protective commensal species. The ‘leaky’ gut, Th17 cell expansion, IFN-γ pathway activation and molecular mimicry associated with gut microbiota dysbiosis play an inconvenient role in the pathogenesis of SLE. Despite these findings, it remains unclear whether translocation of microbial species or their products from the gut into other organs occurs and to what extent sex-specific differences occur in human SLE patients. Addressing these questions may provide new insights into the in-depth mechanisms that lead to the onset of SLE and the differences in the clinical presentation of SLE.

**METABOLIC PERTURBATIONS LINKED TO SLE DEVELOPMENT**

The nature of the intestinal microbiota to coevolve with the host is essential for energy capture by digestion enzymes that do not...
exist in the human genome. Bacterial metabolites have significant effects on the metabolic pathways of dietary carbohydrates, fat, protein and vitamins (78). A mounting array of studies has revealed that patients with SLE have abnormal metabolism compared to the general population (79–81). These metabolite changes are indicated in amino acid metabolism, glycometabolism, lipid metabolism and carbohydrate metabolism. Here, we focus on current research evaluating the disturbance or roles of lipids, short-chain fatty acids and amino acids in the pathogenesis of lupus.

**Lipoprotein Metabolism**

Lipoprotein particles are synthesized in the liver and intestine and are composed of lipids (such as phospholipids, cholesterol and triglycerides) and apolipoproteins (82). The gut microbiota has the ability to modulate dietary lipid composition, digestion, and absorption, potentially altering intestinal lipoprotein formation (83) (84). Available evidence suggests that patients suffering from SLE are more prone to develop lipid profile disorders in both serum and faeces (85) (35). Enriched lipids accounted for 65% of all changed metabolites in serum from SLE patients. In addition, some bile acids, including deoxycholic acid, GCA, isohydroxyacetic acid and arachidonic acid, were significantly correlated with the SLEDAI score. Increased levels of primary bile acids, including cholic acid (CA), glycolic acid (GCA), taurocholic acid (TCA) and glycochenodeoxycholic acid (GCDCa), were also observed in faeces from SLE patients, and they showed fine power to predict the SLEDAI score in a multiple linear regression model (35). It is worth noting that bile acids are important signalling molecules and exert functions through activation of farnesoid X receptor (FXR), GPCR (also known as TGR5) and vitamin D receptor (VDR) (86). FXR has been reported to be downregulated in SLE patients as well as MRL/lpr lupus models with liver dysfunction. Administration of the FXR agonist chenodeoxycholic acid (CDCA) suppresses inflammatory cytokines such as TNF-α, IFN-γ, and IL-6 in mice (87). A recent study also identified the modulatory effect of bile acids on gut immunity. Derivatives of lithocholic acid (LCA), 3-oxoLCA and isooalloLCA can inhibit the differentiation of Th17 cells by directly binding to the key transcription factor retinoid-related orphan receptor-γt (RORγt). Moreover, they enhanced FOXP3 expression by producing mitochondrial reactive oxygen species (mitoROS), leading to the expansion of Treg cells (88). Another study demonstrated that secondary bile acids can activate RORγt regulatory T cells via VDR in the colonic lamina propria of mice (89). In a separate study, researchers identified another type of bile acid, secondary BA 3β-hydroxydeoxycholic acid (isoDCA), which can induce peripheral Treg (pTreg) generation in the large intestine. The microbial fermentation of isoDCA can confer upon an anti-inflammatory profile in dendritic cells to maintain intestinal homeostasis (90). To date, there is still a lack of systemic and mechanistic studies on how lipids, particularly bile acids, contribute to the aetiology of SLE development, although lipid profile changes have been observed in those patients. Increasing evidence of the immune regulatory effect of lipid metabolites from other disease studies or in vitro studies provides us with a plausible direct elucidation of the molecular mechanisms by which the gut microbiome participates in SLE development by affecting lipid metabolism.

**Short-Chain Fatty Acids (SCFAs)**

A mounting array of evidence indicates that SCFAs produced by microbes are crucial executors of the influence of intestinal bacteria on host health and disease (91, 92). SCFAs, most commonly acetate, propionate and butyrate, are the end products of dietary fibres produced by intestinal microbiota fermentation in the colon. Apart from the energy provider for colonocytes (93) and the property of promoting epithelial barrier function (94), the prominent role of SCFAs in modulating inflammation has been comprehensively reviewed elsewhere (95–97). In brief, SCFAs may serve as ligands for G-protein coupled receptors (GPCRs), including GPR41, GPR43 and GPR109A, and exert anti-inflammatory and immune regulatory effects to maintain host physiological status (98–101). The possible mechanisms by which SCFAs modulate immune homeostasis include 1) maintaining intestinal epithelial integrity and protecting against pathogen infection (102, 103); 2) improving the inflammatory environment in the host, such as reducing proinflammatory cytokine production, including IL-6, IL-12, IL-17, IFN-γ, and tumour necrosis factor-α (TNF-α), and increasing anti-inflammatory cytokine production, including TGF-β and IL-10 (96, 104–107); and 3) inducing tolerogenic and anti-inflammatory phenotypes in various immune cells, including Foxp3+ Treg cells, B cells and macrophages, in a GPR43-dependent manner or by histone HDAC6 and HDAC9 inhibition (108). In SLE, researchers found that the metabolic alterations associated with active disease include higher levels of 2-hydroxyisobutyrate and glutamate and lower levels of citrate, glycerol, linoleic acid, and propylparaben in serum (109). Of note, serum 2-hydroxyisobutyrate increased significantly in active patients compared with healthy individuals and inactive patients (109). Moreover, 2-hydroxyisobutyrate upregulation was also identified in the urine of SLE patients in another study published by the same group (110). As a cellular short-chain fatty acid, 2-hydroxyisobutyrate is produced mainly from microbial degradation of dietary proteins, and its presence in urine has been linked with Faecalibacterium prausnitzii (111), a human Clostridia strain well known for enhancing regulatory cell functions (112). The increased blood level of 2-hydroxyisobutyrate likely reflects altered gut microbial metabolism or is accompanied by increased gut permeability. Another recent study reported that supplementation with a high fibre-rich diet improved lupus-related disease manifestations in a Toll-like receptor 7 (TLR7)-dependent lupus-like mouse model. There were enriched gut commensals Lactobacillus reuteri (L. reuteri) in these lupus mice, which exacerbated lupus disease and worsened host immune mechanisms, including increasing pDCs and type I IFN gene expression. Dietary intervention with resistant starch (RS), which promotes the intestinal microbiota to ferment fibre into SCFAs, suppresses the abundance of L. reuteri, ameliorates lupus-like disease, downregulates type I IFN pathways and reduces lupus-related mortality (32). Fibre-derived SCFAs can also affect B cell differentiation processes that critically underpin effective T-dependent and T-independent antibody responses, leading to a reduction in autoantibodies and preventing disease manifestations.
in lupus-prone MRL/Faslpr/lpr and NZB/W F1 mice (113). Together, the above information indicates SCFA alterations and their beneficial immune regulatory roles and therapeutic potential in SLE.

**Tryptophan Metabolism**
Tryptophan, one of the nine essential amino acids, cannot be naturally synthesized by humans, and as a result, it indispensably relies on dietary supplementation and degradation by intestinal microbiota. The metabolism of tryptophan and its metabolites is dependent on its absorption into the gut by intestinal microbiota and is closely linked to autoimmunity. Previous studies identified lower concentrations of tryptophan but higher kynurenine levels in the sera of lupus patients (114). Such findings indicate that tryptophan and the microbiota species that metabolize this amino acid may be implicated in the immune responses of SLE.

The TC mouse model expresses three lupus susceptibility loci from the lupus-prone NZM2410 mouse on the C57BL/6 background (68). The TC mouse model exhibits altered microbial communities. Faecal microbiota transplantation from aged TC mice to healthy GF B6 mice resulted in higher serum anti-dsDNA antibodies and antinuclear autoantibodies as well as the expansion of germinal centre B cells and Tfh cells. Moreover, metabolomic screening identified changes in the amount of tryptophan and its metabolites present in the subjects, including higher kynurenine levels and lower 5-HT expression in the sera and faeces of TC mice compared to B6 mice. In addition, antibiotic treatment could restore the faecal tryptophan of TC mice to normal, and dietary tryptophan restriction exerted a protective effect on lupus progression (63). A high-tryptophan diet was also found to be associated with a more severe disease phenotype and the expansion of *Prevotella, Paraprevotella*, and/or *Lactobacillus* species in TC mouse faeces and induced autoimmunity disorder after faecal transfer in GF B6 mice (Table 2) (63).

Multiple mechanisms have been proposed to account for the involvement of tryptophan in lupus progression. Tryptophan degradation is linked to T cell dysfunction (114) through the kynurenine pathway, which has been shown to induce indole derivatives in patients with SLE (115). Additionally, some species of *Prevotella, Paraprevotella*, or *Lactobacillus* found to be expanded in the gut of TC mice are associated with tryptophan catabolism (116–118). Many tryptophan-derived metabolites, including indole-3-aldehyde, indole-3-acetic acid, 3-methylindole, and tryptamine, are aryl hydrocarbon receptor (AhR) ligands. AhR activation could upregulate genes encoding cytokines such as IL-10 that regulate immune tolerance in lupus (119). These findings highlight the notion that modifying gut microbiota could initiate autoimmunity by manipulating tryptophan metabolism.

**GUT MICROBIOTA, A POTENTIAL THERAPEUTIC TARGET FOR SLE?**

Due to the heterogeneity and relapsing-remitting course, SLE patients with lupus need life-long treatment to remain in remission and achieve low disease activity. Therapeutic strategies to manage lupus are highly individualized according to the clinical and/or laboratory presentation of each patient. Currently, the most widely used approaches to manage lupus include administration of glucocorticoids, hydroxychloroquine, immunosuppressive (IS) drugs, and biological agents to improve long-term patient outcomes (120). Notably, there are substantial side effects associated with available treatments and other negative outcomes, such as inducing an infectious rate. These drawbacks make it essential to identify new interventions that are effective, such as targeted drugs, or ways to reduce adverse reactions.

**Treatment Strategy Based on Diet-Induced Microbiota Adjustment**
Dietary interventions have long been considered feasible and economical auxiliary options to improve symptoms in autoimmune diseases such as RA. There are some encouraging results obtained from clinical and laboratory studies, for example, using α-glucosidase inhibitors or high fibre-rich diets for RA therapy (121, 122). All of the mechanistic investigations point to the involvement of gut microbiota in the above treatments. These findings suggest the possibility that dietary-mediated manipulation of gut microbiota would be a plausible preventive strategy for individuals susceptible to SLE. In fact, acidic water changes the composition of the gut microbiota by increasing *Firmicutes* and reducing *Bacteroidetes* in spp. in favour of renal protection, as reported in an experimental study (59). Another study suggests beneficial effects of vitamin A on autoimmune responses, as vitamin An improves lupus symptoms by promoting *lactobacilli* expansion (60). Recently, Zegarra-Ruiz et al. reported that resistant starch diet-derived short-chain fatty acids could suppress *L. reuteri*, a newly identified pathogen in the pathogenesis of SLE. A starch diet, therefore, is capable of ameliorating lupus-related mortality and manifestations by decreasing pDCs and suppressing the type I IFN pathway (32).

**Treatment by Probiotics/Prebiotics**
The use of probiotics or prebiotics is another way to improve microbial-associated disorders. Long-term use of probiotics can regulate inflammatory status and reduce autoantibody production, thereby lessening lupus severity (123). López et al. revealed that microbiota isolated from SLE patient stool samples promoted lymphocyte activation and naïve CD4+ lymphocyte differentiation towards the Th17 subset compared with that isolated from healthy controls. Interestingly, when 5, 10 or 30% of SLE gut microbiota were replaced with the same proportions of *Bifidobacterium bifidum* LMG13195 (Bb) or a mixture of two *Clostridia* strains (CI: *Ruminococcus obeum* DSM25238 and *Blautia cocoides* DSM935), which are known for Treg-inducing effects, Bb and CI significantly reduced CD4+ lymphocyte over-activation and Th17/Th1 balance, respectively (124). Mike et al. showed that ingestion of a diet containing *Lactobacillus casei* (LC) from the weaning period could prolong the lifespan of MRL/lpr mice and prevent the expansion of B220+ T cells in the spleen and mesenteric lymph nodes. Furthermore, intraperitoneal injection of LC into MRL/lpr mice also significantly impaired the proliferative capacities of...
spenocytes and the accumulation of B220+CD4+CD8- T cells with increasing I-A2 macrophages and macrophage colony-forming cells (M-CFCs) (125).

Overall, although research on SLE therapy based on gut microbiota regulation is limited, the existing evidence points to a plausible strategy for SLE treatment. Of course, the underlying mechanisms implicated in the specific diet or prebiotics/probiotics' improving effects on SLE remain to be elucidated, and further systematic research is warranted.

CONCLUSION

The involvement of mucosal microbiomes in the development of SLE has gained increasing attention from rheumatologists and immunologists with the development of new techniques and new advances. Although some recent studies have identified several pathobionts and pathways that are related to local or systemic inflammation processes and immune system dysregulation in animal lupus models (Table 2), it remains to be determined how consistent they are among different patient populations and which microbial antigens drive immune intolerance to produce several lupus-related autoantibodies. Additionally, sex-specific differences in intestinal bacteria are observed in rodent lupus models (Table 2) (64), but the reason behind these differences is not fully understood. The results of association studies should be interpreted with caution, and a larger array of techniques, including a wider use of longitudinal studies and multi-omics data, will be required to solidify the above questions. Over the last decade, it has become increasingly apparent that the gut microbiota interacts with the host across great distances within the body by producing metabolites. However, there are many unknowns about the clear-cut mechanisms by which microbiota-derived metabolites or co-metabolites (such as AhR ligands) affect the immune cell phenotype and function in the process of SLE development. Filling this gap will definitely advance our understanding of the way in which intestinal microbiota participate in the aetiology of SLE. Recent studies highlight innovative microbiota-based therapeutic strategies, including dietary intervention, probiotic/prebiotic supplementation and FMT, which show therapeutic benefits in IBD, obesity, metabolic syndrome and depressive disorder in the clinic (126–130). Thus far, the results from studies of microbiota-based therapy in lupus animal models seem to be positive and provide us with a plausible possibility to develop an innovative SLE treatment method in the future.

AUTHOR CONTRIBUTIONS

LZ and PQ drafted the manuscript. HY and YW collected related literature. YBL and YL supervised the work and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This research was funded by the National Natural Science Foundation of China (No. 81770101, 81403041), Outstanding interdisciplinary project of West China Hospital, Sichuan University (No. ZYJC18024), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Project no. ZYGDI18015). Scientific application and foundation project of Science and Technology Department of Sichuan Province (No. 2020YJ0021), Scientific research project of Health Commission of Sichuan province (No. 20P050).

REFERENCES

1. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, et al. A Volcanic Explosion of Autoantibodies in Systemic Lupus Erythematosus: A Diversity of 180 Different Antibodies Found in SLE Patients. Autoimmun Rev (2015) 14(1):75–9. doi: 10.1016/j.autrev.2014.10.003
2. Han S, Zhuang H, Shumyak S, Yang L, Reeves WH. Mechanisms of Autoantibody Production in Systemic Lupus Erythematosus. Front Immunol (2015) 6:228. doi: 10.3389/fimmu.2015.00228
3. Deng Y, Tsao BP. Updates in Lupus Genetics. Curr Rheumatol Rep (2017) 19(11):68. doi: 10.1007/s11926-017-0695-z
4. Chen L, Morris DL, Vyas TJ. Genetic Advances in Systemic Lupus Erythematosus: An Update. Curr Opin Rheumatol (2017) 29(5):423–33. doi: 10.1097/BOR.0000000000000411
5. Dema B, Charles N. Autoantibodies in SLE: Specificities, Isotypes and Receptors. Antibodies (Basel) (2016) 5(1):2. doi: 10.3390/antib5010002
6. Choi J, Kim ST, Craft J. The Pathogenesis of Systemic Lupus Erythematosus: An Update. Curr Opin Immunol (2012) 24(6):651–7. doi: 10.1016/j.coi.2012.10.004
7. Teryel M, Alarcon-Riquelme ME. The Genetic Basis of Systemic Lupus Erythematosus: What Are the Risk Factors and What Have We Learned. J Autoimmun (2016) 74:161–75. doi: 10.1016/j.jaut.2016.08.001
8. Zhang J, Zhu Q, Meng F, Lei H, Zhao Y. Association Study of TLR-9 Polymorphisms and Systemic Lupus Erythematosus in Northern Chinese Han Population. Gene (2014) 533(1):385–8. doi: 10.1016/j.gene.2013.08.051
9. Parks CG, De Souza Espindola Santos A, Barbhaiya M, Costenbader KH. Understanding the Role of Environmental Factors in the Development of Systemic Lupus Erythematosus. Best Pract Res Clin Rheumatol (2017) 31(3):306–20. doi: 10.1016/j.berh.2017.09.005
10. Tsokos GC. Systemic Lupus Erythematosus. N Engl J Med (2011) 365(22):2110–21. doi: 10.1056/NEJMra1100359
11. Lane N. The Unseen World: Reflections on Leeuwenhoek (1677) ‘Concerning Little Animals’. Philos Trans R Soc Lond B Biol Sci (2015) 370(1666):20140344. doi: 10.1098/rstb.2014.0344
12. Weinstock GM. Genomic Approaches to Studying the Human Microbiota. Nature (2012) 489(7415):230–6. doi: 10.1038/nature11553
13. Human Microbiome Project C. A Framework for Human Microbiome Research. Nature (2012) 486(7402):215–21. doi: 10.1038/nature11209
14. Human Microbiome Project C. Structure, Function and Diversity of the Healthy Human Microbiome. Nature (2012) 486(7402):207–14. doi: 10.1038/nature11234
15. Suau A, Bonnet R, Sutren M, Godeon JI, Gibson GR, Collins MD, et al. Direct Analysis of Genes Encoding 16S rRNA From Complex Communities Reveals Many Novel Molecular Species Within the Human Gut. Appl Environ Microbiol (1999) 65(11):4799–807. doi: 10.1128/AEM.65.11.4799-4807.1999
16. Flint HJ, Scott KP, Louis P, Duncan SH. The Role of the Gut Microbiota in Nutrition and Health. Nat Rev Gastroenterol Hepatol (2012) 9(10):577–89. doi: 10.1038/nrgastro.2012.156
17. Zhang X, Chen BD, Zhao LD, Li H. The Gut Microbiota: Emerging Evidence in Autoimmune Diseases. Trends Mol Med (2020) 26(9):862–73. doi: 10.1016/j.molmed.2020.04.001
Zhang et al. SLE and Gut Microbiota Dysbiosis

Expressed by a Common Human Gut Commensal to Trigger Autoimmunity. *Cell Host Microbe* (2019) 26(1):100–13 e8. doi: 10.1016/j.chom.2019.03.013

Maldonado MA, Kakkaniah V, MacDonald GC, Chen F, Reap EA, Balish E, et al. The Role of Environmental Antigens in the Spontaneous Development of Autoimmunity in MRL-Lpr Mice. *J Immunol* (1999) 162(11):6322–30.

Johnson BM, Gaudreau MC, Al-Gadban MM, Gudi R, Vasu C. Impact of Dietary Deviation on Disease Progression and Gut Microbiome Composition in Lupus-Prone SNF1 Mice. *Clin Exp Immunol* (2015) 181 (2):323–37. doi: 10.1111/cei.12609

Zhang H, Liao X, Sparks JB, Luo XM. Dynamics of Gut Microbiota in Autoimmune Lupus. *Appl Environ Microbiol* (2014) 80(4):7551–60. doi: 10.1128/AEM.02676-14

Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, et al. Control of Lupus Nephritis by Changes of Gut Microbiota. *Science* (2017) 5(1):73. doi: 10.1186/s40168-017-0300-8

Manfredo Vieira S, Hiltenesperger M, Kumar V, Zegarra-Ruiz D, Dehner C, Khan N, et al. Translocation of a Gut Pathobiont Drives Autoimmunity in Mice and Humans. *Science* (2018) 359(6380):1156–61. doi: 10.1126/science.aar7201

Choi SC, Brown J, Gong M, Ge Y, Zadeh M, Li W, et al. Gut Microbiota Dysbiosis and Altered Tryptophan Catabolite Contribute to Autoimmunity in Lupus-Susceptible Mice. *Sci Transl Med* (2020) 12(531):eaaz2220.

Johnson BM, Gaudreau MC, Gudi R, Brown R, Gilkeson G, Vasu C. Gut Microbiota Differently Contributes to Intestinal Immune Phenotype and Systemic Autoimmune Progression in Female and Male Lupus-Prone Mice. *J Autoimmun* (2020) 108:102420. doi: 10.1016/j.jaut.2020.102420

Klaenhammer TR, Kleebezem K, Kakkanaiah V, MacDonald GC, Chen F, Reap EA, Balish E, et al. Lactobacillus Fermentum CECT5716: A Novel Alternative for the Modulation of Lipopolysaccharide Responsive Factor-Like Molecules (Lrf) in Systemic Lupus Erythematosus (sLE). *Infect Immun* (2017) 85(5):1476–87. doi: 10.1128/ai.02676-17

Arai T, Iino H, Tsuji T, Maki H, Kameyama N, Hirai H, et al. Cell Epitope Mimicry Between Sjogren Syndrome Antigen 2 and Sjogren Syndrome Antigen 2-Related Antigen 1. *Sci Immunol* (2016) 1(3):eaaf2894.
97. Abdollahi-Roodzaad S, Abramson SB, Scher JU. The Metabolic Role of the Gut Microbiota in Health and Rheumatic Disease: Mechanisms and Interventions. *Nat Rev Rheumatol* (2016) 12(8):446–55. doi: 10.1038/ nrrheum.2016.68

98. Kobayashi M, Mikami D, Kimura H, Kajiyama K, Morikawa Y, Yokoi S, et al. Short-Chain Fatty Acids, GPR41 and GPR43 Ligands, Inhibit TNF-Alpha-Induced MCP-1 Expression by Modulating P38 and JNK Signaling Pathways in Human Rectal Cystic Epithelial Cells. *Biochem Biophys Res Commun* (2017) 486(2):499–505. doi: 10.1016/j.bbrc.2017.03.071

99. Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, et al. Metabolite-Sensing Receptors GPR43 and GPR109A Facilitate Dietary Fibre-Induced Gut Homeostasis Through Regulation of the Inflammome. *Nat Commun* (2015) 6:6734. doi: 10.1038/ncomms7734

100. Widner B, Sepp N, Kowald E, Ortner U, Wirleitner B, Fritsch P, et al. Enhanced Tryptophan Degradation in Systemic Lupus Erythematosus. *Immunobiology* (2000) 201(5):621–30. doi: 10.1007/s00724-000-00079-0

101. Akesson K, Pettersson S, Stahl S, Suworow I, Hedenstrom M, Ekström S, et al. Kynurenine Pathway Is Altered in Patients With SLE and Associated With Severe Fatigue. *Lupus Sci Med* (2018) 5(1):e000254. doi: 10.1136/lupus-2017-000254

102. Sasaki-Imamura T, Yoshida Y, Suzuki K, Yoshimura F, Kato H. Molecular Basis of Indole Production Catalyzed by Tryptophanase in the Genus Prevotella. *FEMS Microbiol Lett* (2011) 322(1):51–9. doi: 10.1111/j.1574-6968.2011.02329.x

103. Roager HM, Lichten TR. Microbial Tryptophan Catabolites in Health and Disease. *Nat Commun* (2018) 9(1):3294. doi: 10.1038/s41467-018-05470-4

104. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan Catabolites From Microbiota Engage Aryl Hydrocarbon Receptor and Balance Mucosal Reactivity via Interleukin-22. *Immunity* (2013) 39(2):372–85. doi: 10.1016/j.immuni.2013.08.003

105. Shinde R, Hazavek K, Halaby MJ, Kløtseg A, Chakravarty A, da Silva Medina T, et al. Apoptotic Cell-Induced AhR Activity Is Required for Immunological Tolerance and Suppression of Systemic Lupus Erythematosus in Mice and Humans. *Nat Immunol* (2018) 19(6):571–82. doi: 10.1038/s41590-018-0107-1

106. Fanouriakis A, Kostopoulou M, Alunnou A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. *Ann Rheum Dis* (2019) 78(6):736–45. doi: 10.1136/annrheumdis-2019-215089

107. Zhang L, Song P, Zhang X, Metea C, Schleissman M, Karstens L, et al. Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis. *Front Pharmacol* (2019) 10:1684. doi: 10.3389/fphar.2019.001684

108. Bai Y, Li, Marion T, Tong Y, Zais MM, Tang Z, et al. Resistant Starch Intake Alleviates Collagen-Induced Arthritis in Mice by Modulating Gut Microbiota and Promoting Concomitant Propionate Production. *J Autoimmun* (2020) 110:102565. doi: 10.1016/j.jaut.2020.102564

109. Emaezi AN, Mahmoudi M, Montaazi AA, Sehabkar A, Daulab, H, Rastin M. Tolerogenic Probiotics: Potential Immunoregulators in Systemic Lupus Erythematosus. *J Cell Physiol* (2017) 232(8):1994–2007. doi: 10.1002/jcp.25748

110. Lopez P, de Paz B, Rodriguez-Carrio J, Hevia A, Sanchez B, Margolles A, et al. Faecalibacterium Prausnitzii Is an Anti-Inflammatory Commensal Bacterium Identified by Gut Microbiota Analysis of Crohn’s Disease Patients. *Front Immunol* (2019) 8:22. doi: 10.3389/fimmu.2019.000254

111. de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal Microbiota Interventions. *Nat Rev Rheumatol* (2016) 12:175628418990534. doi: 10.1038/nrrheum.2016.186

112. Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, et al. Apoptotic Cell-Induced AhR Activity Is Required for Immunological Tolerance and Suppression of Systemic Lupus Erythematosus in Mice and Humans. *Nat Immunol* (2018) 19(6):571–82. doi: 10.1038/s41590-018-0107-1

113. Fanouriakis A, Kostopoulou M, Alunnou A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. *Ann Rheum Dis* (2019) 78(6):736–45. doi: 10.1136/annrheumdis-2019-215089

114. Zhang L, Song P, Zhang X, Metea C, Schleissman M, Karstens L, et al. Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis. *Front Pharmacol* (2019) 10:1684. doi: 10.3389/fphar.2019.001684

115. Bai Y, Li, Marion T, Tong Y, Zais MM, Tang Z, et al. Resistant Starch Intake Alleviates Collagen-Induced Arthritis in Mice by Modulating Gut Microbiota and Promoting Concomitant Propionate Production. *J Autoimmun* (2020) 110:102565. doi: 10.1016/j.jaut.2020.102564

116. Emaezi AN, Mahmoudi M, Montaazi AA, Sehabkar A, Daulab, H, Rastin M. Tolerogenic Probiotics: Potential Immunoregulators in Systemic Lupus Erythematosus. *J Cell Physiol* (2017) 232(8):1994–2007. doi: 10.1002/jcp.25748

117. Lopez P, de Paz B, Rodriguez-Carrio J, Hevia A, Sanchez B, Margolles A, et al. Th17 Responses and Natural IgM Antibodies Are Related to Gut Microbiota Composition in Systemic Lupus Erythematosus Patients. *Sci Rep* (2016) 6:24072. doi: 10.1038/srep24072

118. Mike A, Nagaoka N, Tagami Y, Miyashita M, Shimada S, Uchida K, et al. Prevention of B220+ T Cell Expansion and Prolongation of Lifespan Induced by Lactobacillus Casei in MRL/lpr Mice. *Clin Exp Immunol* (1999) 117(2):368–75. doi: 10.1111/j.1365-2249.1999.00951.x

119. Pigneur B, Ruenmele FM. Nutritional Interventions for the Treatment of IBD: Current Evidence and Controversies. *Therap Adv Gastroenterol* (2019) 12:175628418990534. doi: 10.1177/1756284818990534

120. Kim B, ChoiHN, Yim JE. Effect of Diet on the Gut Microbiota Associated With Obesity. *J Obes Metab Syndr* (2019) 28(4):216–24. doi: 10.7570/jomes.2019.28.4.216

121. Dash S, Clarke G, Berk M, Jacka FN. The Gut Microbiome and Diet in Psychiatry: Focus on Depression. *Carr Opin Psychiatry* (2015) 28(1):1–6. doi: 10.1097/YCO.0000000000000117

122. Levy AN, Allegretti JR. Insights Into the Role of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. *Therap Adv Gastroenterol* (2019) 12:175628418990534. doi: 10.1177/1756284818990534

123. de Groot PJ, Friesen MN, de Clercq NC, Nieuwdorp M. Fecal Microbiota Transplantation in Metabolic Syndrome: History, Present and Future. *Gut Microbes* (2017) 8(3):253–67. doi: 10.1080/19490976.2017.1293224